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Abstract 
Multiple sclerosis (MS) is a complex neurological disease that affects the central nervous 
system (CNS) resulting in debilitating neuropathology. Pathogenesis is primarily defined by 
CNS inflammation and demyelination of nerve axons. Methionine synthase reductase 
(MTRR) is an enzyme that catalyzes the remethylation of homocysteine (Hcy) to methionine 
via cobalamin and folate dependant reactions. Cobalamin acts as an intermediate methyl 
carrier between methylenetetrahydrofolate reductase (MTHFR) and Hcy. MTRR plays a 
critical role in maintaining cobalamin in an active form and is consequently an important 
determinant of total plasma Hcy (pHcy) concentrations. Elevated intracellular pHcy levels 
have been suggested to play a role in CNS dysfunction, neurodegenerative, and 
cerebrovascular diseases. Our investigation entailed the genotyping of a cohort of 140 cases 
and matched controls for MTRR and MTHFR, by restriction length polymorphism (RFLP) 
techniques. Two polymorphisms: MTRR A66G and MTHFR A1298C were investigated in an 
Australian age and gender matched case-control study. No significant allelic frequency 
difference was observed between cases and controls at the α = 0.05 level (MTRR χ2 = 0.005, 
P = 0.95, MTHFR χ2 = 1.15, P = 0.28). Our preliminary findings suggest no association 
between the MTRR A66G and MTHFR A1298C polymorphisms and MS.  
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1. Introduction 
Multiple sclerosis (MS) is a complex neurological disease that affects the central nervous 
system (CNS) resulting in debilitating neuropathology. Pathogenesis is primarily defined by 
CNS inflammation and demyelination of nerve axons. The precise etiology of MS remains 
elusive with a complex interplay between environmental factors, genetic susceptibility, and 
age-dependant exposure to viral infection postulated [1]. A significant genetic component has 
been demonstrated by studies examining familial concordance rates with risk being up to 300-
fold increased in monozygotic twins and 20–40-fold increased for first-degree relatives as 
compared to a general population prevalence of 0.1% [2]. 
Methionine synthase reductase (MTRR) is an enzyme that catalyzes the 
remethylation of homocysteine (Hcy) to methionine via a cobalamin and folate dependant 
reaction. Hcy is an intermediate in the folate, vitamin B12, and B6 dependent pathways of 
one-carbon and sulfur amino acid metabolism [3]. Cobalamin acts as an intermediate methyl 
carrier between methylenetetrahydrofolate reductase (MTHFR) and Hcy [4]. The cobalamin 
cofactor cycles between cob(I)alamin and methylcob(III)alamin. Cob(I)alamin is a strong 
reductant and over time becomes oxidised to produce an inactive cob(II)alamin form of 
methionine synthase [5]. MTRR plays a critical role in maintaining cobalamin in an active 
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form and is consequently an important determinant of total plasma Hcy (pHcy) concentration. 
Elevated intracellular pHcy has been implicated in CNS dysfunction, neurodegenerative, and 
cerebrovascular disease. Dysfunction is thought to result from vasotoxic and neurotoxic 
effects of elevated Hcy, inhibition of the methylation of myelin basic protein (MBP) and 
membrane phospholipids, and disruption of biogenic amine metabolism [6]. 
The A1298C polymorphism in the MTHFR gene has been associated with 
hyperhomocysteineemia [7]. The A1298C allele is characterized by a point mutation at 
position 1298 of the MTHFR gene (located 1p36.3) causing the replacement of glutamine by 
alanine in the corresponding enzyme [8]. The A66G polymorphism in the gene MTRR 
(located 5p15.3) alters an isoleucine into a methionine residue. The 66G variant may 
constitute a functional mutation associated with a reduced reductive repair of methionine 
synthase due to the crucial localization of methionine synthase reductase in the enzyme [9]. 
We present an investigation of the possible association of the MTHFR A1298C and MTRR 
A66G polymorphisms with MS in a case-control study of an Australian cohort. 
2. Materials and methods 
2.1. Study population 
Griffith University's Ethics Committee approved research involving human experimentation. 
Informed consent was obtained from all participants. The case-control populations consisted 
of 140 MS patients and 140 healthy controls, which had been matched for age, gender, and 
ethnicity (Caucasian). The MS population was initially obtained from the Multiple Sclerosis 
Clinic at the Royal Brisbane Hospital; all samples were procured from patients residing in the 
South East Queensland region. The populations consisted of 75% females and 25% males, 
and were subcategorized based on clinical course: Relapsing-Remitting (RR), Secondary-
Progressive (SP), and Primary-Progressive (PP). Frequencies were: RR = 40%, SP = 36%, 
and PP = 24%. The matched control (age ± 5 years, gender, and ethnicity) population samples 
were obtained via the Genomics Research Centre Clinic, Southport. Genomic DNA was 
extracted from peripheral blood using a standard salting-out procedure. 
2.2. Genotyping 
Genomic DNA was used as a template to generate polymerase chain reaction (PCR) products 
for subsequent restriction enzyme digest and genotyping. Kara et al. and Feix et al. have 
previously described PCR primers for MTHFR and MTRR, respectively and adaptations of 
their genotyping methods were used for this study [10] and [3]. Primers for MTHFR were: 
forward 5'-CTT TGG GGA GCT GAA GGA CTA CTA C-3', reverse 5'-CAC TTT GTG 
ACC ATT CCG GTT TG-3'. Primers for MTRR were: forward 5'-GCA AAG GCC ATC 
GCA GAA GAC AT-3', reverse 5'-AAA CGG TAA AAT CCA CTG TAA CGG C-3'. 
Primers were obtained from Proligo Primers and Probes (Sigma-Aldrich). Assay conditions 
were optimised with thermal cycling conditions for MTHFR consisting of 95 °C for 3 min, 
then 40 cycles of 94 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min, with a final extension of 
72 °C for 7 min, and MTRR consisting of 95 °C for 2 min, then 40 cycles of 95 °C for 1 min, 
60 °C for 1 min, 72 °C for 1 min, with a final extension of 72 °C for 2 min. MTHFR and 
MTRR PCR products were resolved on a 2%, and 5% high range agarose gel (Progen 
Biosciences) yielding 163 bp and 118 bp amplicons, respectively. Restriction enzyme digest 
of the MTHFR product was with MboII (Fermentas Life Science), and the MTRR product 
with NspI (New England Biolabs). MTHFR A1298A produced five fragments: 56, 31, 30, 28, 
and 18 bp, whilst A1298C produced six fragments: 84, 56, 31, 30, 28, and 18 bp. MTHFR 
digest products were resolved using an 8% resolution plus agarose gel (Progen Biosciences). 
The MTRR sense-primer introduced a mismatch at the 3rd nucleotide (from the 3' end) 
creating a restriction site for the NspI enzyme whenever the G allele was present. In the 
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presence of the A allele the 118 bp product remained uncleaved, in the presence of the G 
allele two fragments were produced: 24 and 94 bp. MTRR digest products were resolved 
using a 5% resolution plus agarose gel (Progen Biosciences). 
3. Statistical analysis 
Descriptive statistics were explored using the SPSS Standard Package (Version 11.0 for Mac 
OS X). Genotype and allele frequencies were investigated using standard Chi-square (χ2) 
analysis using Microsoft Excel. Genotype distributions were checked for Hardy–Weinberg 
equilibrium. 
3.1. Exclusion criteria for statistical analysis 
Of the cohort of 140 cases/controls, 10 cases and 9 matched controls (MTHFR) and 17 cases 
and 16 matched controls (MTRR) were excluded due to genotyping difficulties, leaving 130 
cases and 131 matched controls (MTHFR) and 123 cases and 124 matched controls (MTRR) 
for final analysis. 
TABLE 1. Genotype and allele frequencies for MTHFR  
 Genotype frequencies 
 
N Allele frequencies 
 
 AA AC CC  A C N 
Control 63 (48%) 49 (37%) 19 (15%) 131 175 (67%) 87 (33%) 262
MS 53 (41%) 56 (43%) 21 (16%) 130 162 (62%) 98 (38%) 260
 χ2 = 1.42, P = 0.49 (α = 0.05)  χ2 = 1.15, P = 0.28 (α = 0.05)
 
 
TABLE 2. Genotype and allele frequencies for MTRR  
 
 Genotype frequencies 
 
N Allele frequencies 
 
 AA AG GG  A G N 
Control 47 (38%) 64 (52%) 13 (10%) 124 158 (64%) 90 (36%) 248 
MS 49 (40%) 58 (47%) 16 (13%) 123 156 (63%) 90 (37%) 246 
 χ2 = 0.64, P = 0.73 (α = 0.05)  χ2 = 0.005, P = 0.95 (α = 0.05) 
4. Results 
Genotypes were determined after PCR amplification and restriction enzyme cutting prior to 
standard agarose gel electrophoresis. Results for genotype and allele frequency are detailed in 
Table 1 and Table 2. Genotype frequencies for both the case and control groups, for both 
markers conformed to Hardy–Weinberg equilibrium expectations. The observed control 
frequencies for this study also conformed with independent studies [3] and [10]. There was no 
statistically significant difference between case and control allele frequencies for either the 
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MTHFR (χ2 = 1.15, P = 0.28, α = 0.05); or MTRR (χ2 = 0.005, P = 0.95, α = 0.05); tested 
variants. For MTHFR, the A allele was more frequently observed than the C allele with very 
similar count in the cases and controls (A = 0.67 and 0.62). Similarly, for the MTRR variant, 
the A allele was more frequent than the G allele (A = 0.64 and 0.63) but similar in both cases 
and controls.  
5. Discussion 
MS remains a paradigm of complex disease with variable clinical expression and 
unpredictable course. Disease susceptibility is partly genetically determined, however the 
underlying molecular mechanisms of MS pathogenesis remain unidentified [11]. In vitro 
studies have demonstrated the ability of Hcy to induce neurotoxicity through over-stimulation 
of N-methyl-d-aspartate (NMDA) receptors resulting in neuronal damage due to excessive 
Ca2+ influx and induction of reactive oxygen species [12]. MTHFR deficiency is the most 
common genetic cause of hyperhomocysteinemia [13]. Homocysteine may also sensitize 
neurons to oxidative stress via oxidation of sulfhydryl groups subsequently resulting in 
generation of reactive oxygen species such as superoxide and hydrogen peroxide [14]. The 
A1298C mutation in MTHFR has previously been associated with hyperhomocyteinemia [7]. 
MTRR plays a crucial role in homocysteine metabolism and is necessary to maintain the 
function of methionine synthase [15]. It has previously been hypothesized that the MTRR 
A66G variant may constitute a functional mutation associated with a reduced reductive repair 
of methionine synthase due to the crucial localization of methionine synthase reductase in the 
enzyme [9]. 
We investigated the MTHFR A1298C and the MTRR A66G variants for association with MS 
in an Australian case-control cohort. The findings of this study suggest no association with 
the two tested markers and MS in our population. No statistically significant difference was 
observed by genotype or allele frequencies for either marker between our cases and controls. 
Despite these findings, it is possible that other variants in MTHFR and MTRR may be 
associated with MS or in fact other neurodegenerative disorders. The MTHFR variant C66T 
has been reported to be positively associated with schizophrenia [16]. An American study 
further supports the association that a folate-sensitive defect in homocysteine metabolism 
contributes to cases of that disease [17]. An Irish study of 601 participants has reported a 
significant association between elevated pHcy levels and another variant of MTRR, A66G 
[4]. Lindenbaum and colleagues have suggested that measurement of pHcy levels before and 
after treatment can be valuable for confirmation of a differential diagnosis of neuropsychiatric 
disorder in patients presenting with paresthesia, sensory loss, ataxia, and dementia [18]. A 
recent study that confirmed elevated pHcy levels in MS patients concluded that the finding is 
unlikely to be related to immune activation, oxidative stress, or deficiencies in vitamin B6, 
B12, or folate [19]. Other investigations also support the finding of elevated homocysteine 
levels in MS patients compared with healthy controls [20], [21] and [22]. It is hypothesized 
that the nervous system may be particularly sensitive to pHcy as it promotes excitotoxicity by 
stimulation of NMDA receptors and damages neuronal DNA hence triggering apoptosis in 
neuronal cells [14] and [23]. Ergo, although our findings suggest no association between 
MTHFR A1298C and MTRR A66G and MS, other variants associated with the homocysteine 
metabolism cascade may still contribute to MS susceptibility.  
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